The National Institute of Diabetes and Digestive and Kidney Diseases confirms that severe cases may progress to gastroparesis or stomach paralysis
Nevertheless, the integration of two-year outcomes, rigorous propensity matching, millions of clinical notes analyzed through validated AI models, and one of the largest GLP-1RA-treated cohorts studied to date provides a robust characterization of real-world treatment heterogeneity
Ethics declarations Ethics Approval All relevant ethics approvals are from original genome-wide association studies
Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Bydureon, Adlyxin, Tanzeum, Eperzan, Orfoglip, and Retara are registered trademarks of their respective owners
Semaglutide may interact with Leydig cells, which express the glucagon-like peptide-1 (GLP-1) receptor and regulate GLP-1 secretion